Smriti Srivastava
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Smriti Srivastava has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Purva Mathur
Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
8 shared publications - Neha Sharad
Department of Microbiology, All India Institute of Medical Sciences, Deoghar, Jharkhand, 814152, India
5 shared publications Aparna Ningombam
Department of Laboratory Medicine, JPNATC, All India Institute of Medical Sciences, New Delhi, India
3 shared publicationsRajesh Malhotra
Department of Orthopaedics, AIIMS, New Delhi, India
3 shared publications- Rajesh Malhotra
Department of Orthopaedics, All India Institute of Medical Sciences, New Delhi 110029, Delhi, India
3 shared publications - Aparna Ningombam
Laboratory Medicine, Jai Prakash Narayan Apex (JPNA) Trauma Centre, All India Institute of Medical Sciences, New Delhi
2 shared publications
Latest Publications
- Open Access
- 18 July 2024
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 28, 100450
Surveillance of ventilator associated pneumonia in a network of indian hospitals using modified definitions: a pilot study
- 18 July 2024
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 28, 100450
Open AccessSurveillance of ventilator associated pneumonia in a network of indian hospitals using modified definitions: a pilot study
- Open Access
- 4 June 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (6) , e0375923
Utility of a multiplex pathogen detection system directly from respiratory specimens for treatment and diagnostic stewardship
The availability of syndrome-based panels for various ailments has widened the scope of diagnostics in many clinical settings. These panels can detect a multitude of pathogens responsible for a particular condition, which can lead to a timely diagnosis and better treatment outcomes. In contrast to traditional identification methods based on pathogen growth on culture, syndrome-based panels offer a quicker diagnosis, which can be especially beneficial in situations requiring urgent care, such as intensive care units. One such panel is the Biofire Filmarray Pneumonia plus Panel (BFP), which we have compared against microbiological culture and identification. The lower respiratory samples from patients were tested with BFP, culture, and identification with culture considered the gold standard. The phenotypic antibiotic susceptibility results (Vitek 2) were compared with the antimicrobial resistance (AMR) genes detected in BFP. Statistical analysis was carried out using GraphPad 7.0 and MS Excel (Microsoft Inc.). The results showed a positive percent agreement of 100% and a negative percent agreement of 47.8% with an overall agreement of 76.72% compared to culture. BFP was better at identifying fastidious bacteria, and the agreement with culture was higher for high bacterial identification numbers (10 7 and 10 6 ). There was also a correlation between the number of pathogens detected and growth in culture. Carbapenemase genes were detected in around 80% of phenotypically resistant samples and correlated with in-house PCR 60% of the time. Hence, BFP results need to be interpreted with caution especially when multiple pathogens are detected. Similarly, the presence or absence of AMR genes should be used to guide the therapy while being watchful of unusual resistance or susceptibility. The cost constraints and low throughput call for patient selection criteria and prioritization in emergency or resource-limited conditions. IMPORTANCE: Application of syndrome-based panels in clinical microbiology is of huge support in infectious conditions requiring urgent interventions, such as pneumonia. Interpreting the results requires caution; hence, we have compared the results obtained from Biofire Filmarray Pneumonia plus Panel with standard microbiological methods.
- 4 June 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (6) , e0375923
Open AccessUtility of a multiplex pathogen detection system directly from respiratory specimens for treatment and diagnostic stewardship
The availability of syndrome-based panels for various ailments has widened the scope of diagnostics in many clinical settings. These panels can detect a multitude of pathogens responsible for a particular condition, which can lead to a timely diagnosis and better treatment outcomes. In contrast to traditional identification methods based on pathogen growth on culture, syndrome-based panels offer a quicker diagnosis, which can be especially beneficial in situations requiring urgent care, such as intensive care units. One such panel is the Biofire Filmarray Pneumonia plus Panel (BFP), which we have compared against microbiological culture and identification. The lower respiratory samples from patients were tested with BFP, culture, and identification with culture considered the gold standard. The phenotypic antibiotic susceptibility results (Vitek 2) were compared with the antimicrobial resistance (AMR) genes detected in BFP. Statistical analysis was carried out using GraphPad 7.0 and MS Excel (Microsoft Inc.). The results showed a positive percent agreement of 100% and a negative percent agreement of 47.8% with an overall agreement of 76.72% compared to culture. BFP was better at identifying fastidious bacteria, and the agreement with culture was higher for high bacterial identification numbers (10 7 and 10 6 ). There was also a correlation between the number of pathogens detected and growth in culture. Carbapenemase genes were detected in around 80% of phenotypically resistant samples and correlated with in-house PCR 60% of the time. Hence, BFP results need to be interpreted with caution especially when multiple pathogens are detected. Similarly, the presence or absence of AMR genes should be used to guide the therapy while being watchful of unusual resistance or susceptibility. The cost constraints and low throughput call for patient selection criteria and prioritization in emergency or resource-limited conditions. IMPORTANCE: Application of syndrome-based panels in clinical microbiology is of huge support in infectious conditions requiring urgent interventions, such as pneumonia. Interpreting the results requires caution; hence, we have compared the results obtained from Biofire Filmarray Pneumonia plus Panel with standard microbiological methods.
- Open Access
- 30 April 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (04) , 636-639
Kodamaea ohmeri: A rare yeast causing invasive infections in immunocompromised patients
Introduction: Kodamaea ohmeri is a rare, recognized pathogen that has previously been isolated from environmental sources. The patients commonly affected by this yeast include immunocompromised as well as immunocompetent patients having several associated risk factors. Methodology: We report three cases in which K. ohmeri was isolated from blood using Bact T/ALERT. Identification was carried out by MALDI-TOF MS (Vitek-MS, BioMérieux, Marcy-l’Etoile, France) in addition to color characteristics on chromogenic media. The patients had diminished immune response on account of a multitude of comorbidities. Results: K. ohmeri can be misidentified as Candida tropicalis, Candida albicans, or Candida hemolounii by conventional methods; correct and timely identification can be achieved by MALDI-TOF MS. Antifungal susceptibility breakpoints for K. ohmeri are currently not defined. An Echinocandin was added to the treatment regimen of all three of the cases. Conclusions: Identification of K. ohmeri using conventional methods is difficult and unusual yeasts should be carefully observed, especially upon prolonged incubation.
- 30 April 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (04) , 636-639
Open AccessKodamaea ohmeri: A rare yeast causing invasive infections in immunocompromised patients
Introduction: Kodamaea ohmeri is a rare, recognized pathogen that has previously been isolated from environmental sources. The patients commonly affected by this yeast include immunocompromised as well as immunocompetent patients having several associated risk factors. Methodology: We report three cases in which K. ohmeri was isolated from blood using Bact T/ALERT. Identification was carried out by MALDI-TOF MS (Vitek-MS, BioMérieux, Marcy-l’Etoile, France) in addition to color characteristics on chromogenic media. The patients had diminished immune response on account of a multitude of comorbidities. Results: K. ohmeri can be misidentified as Candida tropicalis, Candida albicans, or Candida hemolounii by conventional methods; correct and timely identification can be achieved by MALDI-TOF MS. Antifungal susceptibility breakpoints for K. ohmeri are currently not defined. An Echinocandin was added to the treatment regimen of all three of the cases. Conclusions: Identification of K. ohmeri using conventional methods is difficult and unusual yeasts should be carefully observed, especially upon prolonged incubation.
- 1 September 2023
- Published by Bentham Science Publishers Ltd. in Infectious Disorders - Drug Targets
- Vol. 23 (6) , 1
E. hirae Causing Biliary Tract Infection in a Patient with Cholangiocarcinoma: A Case Report
Introduction: E. faecium and E. faecalis are the common species of Enterococcus responsible for the majority of infections. Earlier, species other than the common ones were usually unidentified and reported as Enterococcus species. However, modern equipment, like MALDI-TOF and VITEK2, have been utilitarian, helping us to identify the previously unidentified species. E. hirae is an organism seldom reported to cause human infections. Here, we report a case of a biliary tract infection in a female patient with cholangiocarcinoma caused by E. hirae. Case: A 56-year-old female presented with fever and abdominal pain. Bile aspirated during the ERCP was received in our laboratory. The gram stain of the bile sample revealed abundant polymorphonuclear leucocytes along with gram-positive diplococci. The organism failed to grow on MacConkey agar. On blood agar, non-hemolytic colonies grew. The organism was identified as E. hirae by MALDI-TOF MS. The antibiotic susceptibility performed using VITEK2 revealed it to be resistant to high-level gentamicin and susceptible to all remaining drugs. She was successfully treated with oral ciprofloxacin for the infection. Discussion: Bile is colonized with bacteria due to obstruction in the biliary tree, leading to cholangitis. This causes bacterial proliferation and translocation of bacteria into the systemic circulation. Our case was resistant to high-level gentamicin, while all previously reported cases were susceptible. The resistant isolates of E. hirae being isolated from cattle and their surroundings amidst the rampant use of antibiotics in livestock can pose a difficult situation for humans. Thus, there should be regulations on antibiotic usage in livestock. Cases like these should be reported and recognized for their potential to cause outbreaks if they remain unreported. Conclusion: Thus, E. hirae, when encountered, should not be ignored but considered a pathogen and reported. The presence of drug-resistant organisms in cattle and their surroundings, their zoonotic potential to cause infections in humans, and the uncontrolled usage of antibiotics in livestock are causes for concern. Thus, we need to be more vigilant regarding it in the future.
- 1 September 2023
- Published by Bentham Science Publishers Ltd. in Infectious Disorders - Drug Targets
- Vol. 23 (6) , 1
E. hirae Causing Biliary Tract Infection in a Patient with Cholangiocarcinoma: A Case Report
Introduction: E. faecium and E. faecalis are the common species of Enterococcus responsible for the majority of infections. Earlier, species other than the common ones were usually unidentified and reported as Enterococcus species. However, modern equipment, like MALDI-TOF and VITEK2, have been utilitarian, helping us to identify the previously unidentified species. E. hirae is an organism seldom reported to cause human infections. Here, we report a case of a biliary tract infection in a female patient with cholangiocarcinoma caused by E. hirae. Case: A 56-year-old female presented with fever and abdominal pain. Bile aspirated during the ERCP was received in our laboratory. The gram stain of the bile sample revealed abundant polymorphonuclear leucocytes along with gram-positive diplococci. The organism failed to grow on MacConkey agar. On blood agar, non-hemolytic colonies grew. The organism was identified as E. hirae by MALDI-TOF MS. The antibiotic susceptibility performed using VITEK2 revealed it to be resistant to high-level gentamicin and susceptible to all remaining drugs. She was successfully treated with oral ciprofloxacin for the infection. Discussion: Bile is colonized with bacteria due to obstruction in the biliary tree, leading to cholangitis. This causes bacterial proliferation and translocation of bacteria into the systemic circulation. Our case was resistant to high-level gentamicin, while all previously reported cases were susceptible. The resistant isolates of E. hirae being isolated from cattle and their surroundings amidst the rampant use of antibiotics in livestock can pose a difficult situation for humans. Thus, there should be regulations on antibiotic usage in livestock. Cases like these should be reported and recognized for their potential to cause outbreaks if they remain unreported. Conclusion: Thus, E. hirae, when encountered, should not be ignored but considered a pathogen and reported. The presence of drug-resistant organisms in cattle and their surroundings, their zoonotic potential to cause infections in humans, and the uncontrolled usage of antibiotics in livestock are causes for concern. Thus, we need to be more vigilant regarding it in the future.
- 5 July 2023
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 46, 100421
Identification of Candida auris by PCR and assessment of biofilm formation by crystal violet assay
- 5 July 2023
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 46, 100421
Identification of Candida auris by PCR and assessment of biofilm formation by crystal violet assay
- Open Access
- 10 February 2023
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 8 (3) , 645-648
Tuberculous Pericarditis in a Patient with COVID-19
A 23-year-old male presenting to the emergency department with cough and fever for 2 days tested positive for COVID-19 by rapid antigen test (SD Biosensor, Roche Diagnostics India), per our hospital policy. He was admitted to our dedicated COVID-19 Centre, where the diagnosis was confirmed by reverse transcription-PCR. A commercial real-time reverse transcription-PCR kit (BGI Genomics Co. Ltd.), which has Emergency Use Authorization from the US Food and Drug Administration and approval from the Indian Council of Medical Research) was used. His past history was remarkable for the diagnosis of acute myeloblastic leukemia (AML) 2 months back, for which he had received induction chemotherapy and was in remission. Past history of tubercular lymphadenitis was also present; however, treatment records were not available. After an initial improvement, he developed sudden-onset chest pain, radiating to the neck, on day 9. An acute coronary syndrome was ruled out by electrocardiogram and serial Troponin I. A two-dimensional transthoracic echocardiography revealed massive circumferential pericardial effusion with a maximum thickness of 9 mm anterior to the right ventricle. A complete blood count showed pancytopenia. No evidence of pneumonia was visible on the chest radiograph. Blood and urine cultures collected on the day had no growth. Pericardiocentesis was performed to drain the fluid; this was transported to the microbiology laboratory for bacterial culture and sensitivity. Considering the patient's history and current status, we considered 4 possible differential diagnoses: community-acquired fastidious bacteria, leukemic pericarditis after a recurrence of AML, tubercular pericarditis, and atypical presentation of COVID-19.
- 10 February 2023
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 8 (3) , 645-648
Open AccessTuberculous Pericarditis in a Patient with COVID-19
A 23-year-old male presenting to the emergency department with cough and fever for 2 days tested positive for COVID-19 by rapid antigen test (SD Biosensor, Roche Diagnostics India), per our hospital policy. He was admitted to our dedicated COVID-19 Centre, where the diagnosis was confirmed by reverse transcription-PCR. A commercial real-time reverse transcription-PCR kit (BGI Genomics Co. Ltd.), which has Emergency Use Authorization from the US Food and Drug Administration and approval from the Indian Council of Medical Research) was used. His past history was remarkable for the diagnosis of acute myeloblastic leukemia (AML) 2 months back, for which he had received induction chemotherapy and was in remission. Past history of tubercular lymphadenitis was also present; however, treatment records were not available. After an initial improvement, he developed sudden-onset chest pain, radiating to the neck, on day 9. An acute coronary syndrome was ruled out by electrocardiogram and serial Troponin I. A two-dimensional transthoracic echocardiography revealed massive circumferential pericardial effusion with a maximum thickness of 9 mm anterior to the right ventricle. A complete blood count showed pancytopenia. No evidence of pneumonia was visible on the chest radiograph. Blood and urine cultures collected on the day had no growth. Pericardiocentesis was performed to drain the fluid; this was transported to the microbiology laboratory for bacterial culture and sensitivity. Considering the patient's history and current status, we considered 4 possible differential diagnoses: community-acquired fastidious bacteria, leukemic pericarditis after a recurrence of AML, tubercular pericarditis, and atypical presentation of COVID-19.
- Open Access
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (6) , e0091922
Secondary Bacterial Infections in Mucormycosis-COVID-19 Cases: Experience during the Second COVID-19 Wave in India
Although our knowledge about COVID-19 and secondary infections in patients is increasing daily, little is known about the secondary infections in COVID-19-mucormycosis patients. Thus, we have intended to share our experience regarding this subgroup.
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (6) , e0091922
Open AccessSecondary Bacterial Infections in Mucormycosis-COVID-19 Cases: Experience during the Second COVID-19 Wave in India
Although our knowledge about COVID-19 and secondary infections in patients is increasing daily, little is known about the secondary infections in COVID-19-mucormycosis patients. Thus, we have intended to share our experience regarding this subgroup.
- Open Access
- 20 October 2022
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (01) , 106-109
Infection Trends, Susceptibility Pattern, and Treatment Options for Stenotrophomonas maltophilia Infections in Trauma Patients: A Retrospective Study
Introduction Stenotrophomonas maltophilia is an emerging environmental, gram-negative, multidrug-resistant organism, associated with risk factors such as prolonged hospitalization, invasive procedures, admission to the intensive care unit, mechanical ventilation, use of indwelling catheters, administration of immunosuppressants or corticosteroids, human immunodeficiency virus infection, underlying malignancy, and organ transplantation. The organism, despite being of low invasiveness in immune-competent individuals, is difficult to treat because of intrinsic resistance to several antimicrobial agents. Materials and Methods This study focuses on commonly encountered resistance from among the isolates over a duration of 7 years from 2012 to 2018, analyzed retrospectively. Identification and susceptibility testing were performed using Vitek 2 (BioMérieux, Marcy-l'Etoile, France). Results Bloodstream infections were found to be most common (52.02%), followed by respiratory infections (35.83%). The median age of the patients was 36 years, and male to female ratio was 143:27. The median duration of hospital stay was 18 days, and mortality was seen in 18.82% of patients. Susceptibility to cotrimoxazole and levofloxacin was seen in 97.1% of isolates (168 out of 173) and 90.1% of isolates (156 out of 173), respectively. Conclusion Despite being effective in a majority of S. maltophilia isolates, both cotrimoxazole and levofloxacin have their shortcomings. Cotrimoxazole is bacteriostatic and can cause bone marrow suppression and resistance to levofloxacin sometimes develops during therapy. Thus, the therapy should be decided considering the characteristics of both of these drugs.
- 20 October 2022
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (01) , 106-109
Open AccessInfection Trends, Susceptibility Pattern, and Treatment Options for Stenotrophomonas maltophilia Infections in Trauma Patients: A Retrospective Study
Introduction Stenotrophomonas maltophilia is an emerging environmental, gram-negative, multidrug-resistant organism, associated with risk factors such as prolonged hospitalization, invasive procedures, admission to the intensive care unit, mechanical ventilation, use of indwelling catheters, administration of immunosuppressants or corticosteroids, human immunodeficiency virus infection, underlying malignancy, and organ transplantation. The organism, despite being of low invasiveness in immune-competent individuals, is difficult to treat because of intrinsic resistance to several antimicrobial agents. Materials and Methods This study focuses on commonly encountered resistance from among the isolates over a duration of 7 years from 2012 to 2018, analyzed retrospectively. Identification and susceptibility testing were performed using Vitek 2 (BioMérieux, Marcy-l'Etoile, France). Results Bloodstream infections were found to be most common (52.02%), followed by respiratory infections (35.83%). The median age of the patients was 36 years, and male to female ratio was 143:27. The median duration of hospital stay was 18 days, and mortality was seen in 18.82% of patients. Susceptibility to cotrimoxazole and levofloxacin was seen in 97.1% of isolates (168 out of 173) and 90.1% of isolates (156 out of 173), respectively. Conclusion Despite being effective in a majority of S. maltophilia isolates, both cotrimoxazole and levofloxacin have their shortcomings. Cotrimoxazole is bacteriostatic and can cause bone marrow suppression and resistance to levofloxacin sometimes develops during therapy. Thus, the therapy should be decided considering the characteristics of both of these drugs.